D. Boral Capital Reaffirms Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $9.00 price target on the stock.

A number of other research firms also recently issued reports on IVVD. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. HC Wainwright lowered their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $7.89.

Invivyd Stock Performance

NASDAQ:IVVD opened at $0.50 on Monday. The company has a market cap of $59.21 million, a PE ratio of -0.25 and a beta of 0.64. The stock has a 50-day simple moving average of $0.54 and a 200 day simple moving average of $0.86. Invivyd has a 52-week low of $0.38 and a 52-week high of $5.20.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 160,400 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Invivyd

A number of large investors have recently added to or reduced their stakes in the business. State Street Corp increased its holdings in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Marshall Wace LLP grew its stake in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after buying an additional 31,992 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Invivyd in the 2nd quarter valued at about $421,000. Cubist Systematic Strategies LLC raised its holdings in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after acquiring an additional 53,499 shares during the period. Finally, Barclays PLC lifted its position in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.